Note : Les descriptions sont présentées dans la langue officielle dans laquelle elles ont été soumises.
CA 02721051 2010-10-08
DESCRIPTION
Title of Invention: AMINOSUGAR COMPOUND AND PROCESS FOR PRODUCTION
THEREOF
Technical Field
[0001]
The present invention relates to an aminosugar compound that is useful as an
active
ingredient for a pharmaceutical composition, particularly a pharmaceutical
composition for
the treatment of diabetes.
Background Art
[0002]
Polysaccharides that have been ingested through a meal are partially digested
by a
saliva-derived a-amylase in the oral cavity and the stomach, and then most of
the
polysaccharides are digested by a pancreas-derived a-amylase in the duodenum
and the
jejunum, thereby being converted to disaccharides or oligosaccharides. These
are
hydrolyzed into monosaccharides by glucosidases represented by maltase and
sucrase, which
are localized in the microvillar membrane of the small intestine epithelium,
and the
.20 monosaccharides are absorbed through the intestinal tract. The absorbed
monosaccharides
are transited into the blood, and when the blood glucose level increases,
insulin is secreted
from the pancreas so as to decrease the sugar release from the liver and also
to increase the
intake of sugar into the muscles or fatty tissues. Thereby, the increased
blood glucose level
is lowered, and the homeostasis is maintained.
[0003]
However, in the pathological condition of diabetes, a patient is in the state
of
suffering from chronic failure of blood glucose control, such as postprandial
hyperglycemia or
interdigestive hyperglycemia, due to the hyposecretion of insulin secretion or
insulin
resistance (hypoactivity of insulin).
[0004] .
In recent years, it was verified by a large-scale clinical trial that
correction of the
postprandial hyperglycemia is important in the suppression of the onset and
progress of
diabetes complications. It has been proved that even a mild degree of
postprandial
hyperglycemia is an independent risk factor for cardiovascular deaths. Under
such
1
CA 02721051 2010-10-08
circumstances, the importance and necessity of medication treatment for
postprandial
hyperglycemia (for example, the state in which the blood glucose level
measured 2 hours after
meal is 200 mg/dL or higher) has come to be recognized.
[0005]
Glucosidase inhibitors, which are digestive enzyme inhibitors, have been put
to actual
clinical use (for example, acarbose or voglibose) as therapeutic drugs for
postprandial
hyperglycemia. However, adverse side effects of the occurrence of symptoms in
the
digestive system (a sense of abdominal fullness, diarrhea, loose stools,
flatulence, obdomial
wind, and the like) caused by glucosidase inhibition have become a problem.
[0006]
Furthermore, another example of a therapeutic drug for postprandial
hyperglycemia
(digestive enzyme inhibitory drug) is an a-amylase inhibitor. While inhibition
of a
glucosidase results in the side-production of large amounts of undigested
oligosaccharides
(disaccharides), inhibition of an a-amylase results in the by-production of
only a small
amount of undigested oligosaccharides (disaccharides), and therefore, it is
expected that the
a-amylase inhibitor can manifest the inhibition of glucose absorption without
causing
symptoms in the digestive system such as diarrhea.
[0007]
Several aminosugar compounds having an a-amylase inhibitory activity have been
reported.
For example, there has been reported a trestatin derivative (the following
formula,
provided that n in the formula represents 1 to 3) isolated from a
actinomycetes belonging to
the genus Streptomyces (Patent Literature 1).
[Chem. 2]
CH 2 OH CH3 CH2OH CH2OH CH(OH OH OH
O O O 0 2OH
OH ~OH OH OH rO H
O N O O 0 0OH
H OH H OH OH n: OH OH
[0008]
A malto-oligosaccharide compound having hexahydro-3,5,6-trihydroxy-lH-azepine
as an essential skeleton has also been reported (Patent Literature 2).
2
CA 02721051 2010-10-08
[Chem. 3]
OH 4OH O O OH OH OH N
H
O O O OH
H O
OH n OH OH OH
(wherein n represents 0 to 3; and X represents H or a hydrophobic group).
[0009]
Furthermore, a compound having a reducing sugar structure at the terminals, in
which
n in the following formula is from 0 to 3, is known (Non-Patent Literature 1).
[Chem. 4]
OH CH OH OH CH OH OH OH OH
3 3
O O O O O O O
OH OH OH OH OH OH OH OH OH OH
N O N O O O O
OH OHH OH OH OHH OH OH n OH OH OH
Acarviostatin IV03 (n=3), which is disclosed in the non-patent Literature, has
a
molecular formula of C94H156N4064, which is identical with the compound of the
invention
wherein n = 4. However, this compound is a compound having a reducing sugar
structure at
the terminals and is therefore different in structure from the compound of the
invention.
[Citation List]
[Patent Literature]
[0010]
Patent Literature 1: JP-A-54-163511
Patent Literature 2: Specification of U.S. Patent No. 6596696
[Non-Patent Literature]
[0011]
Non-Patent Literature 1: Carbohydrate Research, 343 (2008), 882-892
3
CA 02721051 2010-10-08
Summary of the Invention
Problem to Be Solved by the Invention
[0012]
The invention provides a compound that is useful as an active ingredient for a
pharmaceutical composition, particularly a pharmaceutical composition for the
treatment of
diabetes.
Means for Solving the Problem
[0013]
An a-amylase inhibitory drug needs to show stability in the digestive tract.
Being
unstable in the digestive tract implies that there is a possibility that the
degradation product
may be absorbed and may cause unexpected adverse side effects.
The present inventors made an extensive investigation of substances produced
by
microorganisms for the purpose of searching for a medicine, and as a result,
the inventors
found that strain 6982 of a actinomycetes belonging to the genus Streptomyces
produces a
compound having an excellent a-amylase inhibitory activity, thus completing
the invention.
[0014]
Thus, the present invention relates to a compound of formula (I) or a salt
thereof, a
composition comprising a compound of formula (I) or a salt thereof, a
pharmaceutical
composition comprising a compound of formula (I) or a salt thereof, and an
excipient; and a
process for production of a compound of formula (I) or a salt thereof.
[0015]
[Chem. 5]
CH z OH CH3 CH2OH CH2OH CH2OH OH
O O O O OH
OH OH
H (O\N>\OoH
OH H OH OH n 0 OH O OH O OH
(I)
wherein n is 4, 5 or 6.
4
CA 02721051 2010-10-08
[0016]
The present invention also relates to a compound having an a-amylase
inhibitory
activity and having a molecular formula of C94H156N4064, C113H187N5076 or
C132H218N6088
(provided that those compounds having a reducing sugar structure at the
terminals are
excluded), or a salt thereof, the compound being obtainable by culturing a
microorganism
belonging to the genus Streptomyces that produces a compound having an a-
amylase
inhibitory activity or a salt thereof in a medium, and recovering the compound
or a salt
thereof from the culture medium; and a composition comprising the compound or
a salt
thereof.
Moreover, the present invention relates to a pharmaceutical composition for
the
prevention or treatment of diabetes, comprising a compound of formula (I) or a
salt thereof,
i.e., an agent for treating diabetes, comprising a compound of formula (I) or
a salt thereof.
Further, the present invention relates to use of a compound of formula (I) or
a salt
thereof, for the production of a pharmaceutical composition for the prevention
or treatment of
diabetes; use of a compound or a salt thereof, for the prevention or treatment
of diabetes; and
a method for the prevention or treatment of diabetes, the method comprising
administering an
effective amount of a compound of formula (I) or a salt thereof to a patient.
Effect of the Invention
The compound of formula (I) or a salt thereof has an a-amylase inhibitory
action and
can be used as a prophylactic or therapeutic agent for diabetes, obesity, NASH
(non-alcoholic
steatohepatitis) and the like. The compound or a salt thereof is also expected
to be able to
inhibit the absorption of glucose without causing symptoms in the digestive
system such as
diarrhea, unlike the glucosidase inhibitors.
Description of Embodiments
[0018]
[FIG 1] FIG 1 shows the 'H-NMR spectrum of compound A.
[FIG 2] FIG 2 shows the 13C-NMR spectrum of compound A.
[FIG 3] FIG 3 shows the 'H-NMR spectrum of compound B.
[FIG 4] FIG 4 shows the 13C-NMR spectrum of compound B.
[FIG 5] FIG 5 shows the 'H-NMR spectrum of compound C.
[FIG 6] FIG 6 shows the 13C-NMR spectrum of compound C.
5
CA 02721051 2010-10-08
[FIG. 7] FIG. 7 shows the blood glucose elevation suppressive action of the
compound A under a load of carbohydrates. (A) shows the changes over time in
the blood
glucose level, and (B) shows the area-under-curve (AUC).
[FIG 8] FIG 8 shows the insulin elevation suppressive action of the compound A
under a load of carbohydrates. (A) shows the changes over time in the insulin
level, and (B)
shows the AUC.
[FIG. 9] FIG 9 shows the HPLC chromatogram of compound A.
[FIG 10] FIG. 10 shows the HPLC chromatogram of compound B.
[FIG. 11] FIG 11 shows the HPLC chromatogram of compound C.
Embodiment for Carrying Out the Invention
[0019]
For example, in the compound (I) of the invention, a compound in which n is 4
is
represented by the following formula.
[0020]
[Chem. 6]
CH OH CH3 CH2OH CH2OH CH2OH OH
2
O L0H
LO\N>\OoHO
OH O O OH 00 OH
H OH H OH 4 OH
[0021]
The compound of formula (I) can have geometrical isomers. In the present
specification, the compound of formula (I) is described only in one form of
the isomers, but
the present invention includes the other isomers and includes isolated single
examples of the
isomers as well as mixtures thereof.
Furthermore, the compound of formula (I) can have optical isomers based on
asymmetric carbon atom(s). The invention includes isolated single examples of
the optical
isomers of the compound of formula (I) as well as mixtures thereof.
[0022]
The invention also includes pharmaceutically acceptable prodrugs of the
compound
represented by the formula (I). A pharmaceutically acceptable prodrug is a
compound
6
CA 02721051 2010-10-08
having a group that can be converted to an amino group, a hydroxyl group or
the like through
solvolysis or under physiological conditions. Examples of the group forming a
prodrug
include the groups described in Prog. Med., 5, 2157-2161 (1985) or
"Pharmaceutical Research
and Development" (Hirokawa Publishing Company, 1990), Vol. 7 Drug Design, 163-
198.
[0023]
A salt of the compound of formula (I) is a pharmaceutically acceptable salt of
the
compound of formula (I), and optionally forms an acid addition salt. Specific
examples
include the acid addition salts with inorganic acids such as hydrochloric
acid, hydrobromic
acid, hydroiodic acid, sulfuric acid, nitric acid and phosphoric acid; and
with organic acids
such as formic acid, acetic acid, propionic acid, oxalic acid, malonic aid,
succinic acid,
fumaric acid, maleic acid, lactic acid, malic acid, mandelic acid, tartaric
acid,
dibenzoyltartaric acid, ditoluoyltartaric acid, citric acid, methanesulfonic
acid, ethanesulfonic
acid, benzenesulfonic acid, p-toluenesulfonic acid, aspartic acid and glutamic
acid.
[0024]
The invention also includes various hydrates or solvates and crystal
polymorphs of
the compound of formula (I) and salts thereof. The invention also includes
compounds
labeled with various radioactive isotopes or non-radioactive isotopes.
[0025]
In the present specification, the "compound having reducing sugars at the
terminals"
is not particularly limited, but examples thereof include compounds of natural
product and the
like in which sugars having an aldehyde group (or ketone group) that can be
free is present at
the terminals, such as acarbose, acarviostatin 103, acarviostatin 1103,
acarviostatin 11103 and
acarviostatin IV03.
[0026]
(Process for production)
The compound of the invention can be produced by using a microorganism which
belongs to the genus Streptomyces and is capable of producing the compound or
a
pharmaceutically acceptable salt thereof. A preferable example of such a
microorganism is
Streptomyces sp. strain 6982, which belongs to the genus Streptomyces and has
been isolated
from the soil collected at Iriomote Island in Okinawa Prefecture. The
mycological
properties of the subject strain are as follows.
[0027]
Streptomyces sp. strain 6982 was isolated from the soil sample collected at
Iriomote
Island in Okinawa Prefecture. The medium and method for investigating the
morphology,
7
CA 02721051 2010-10-08
culturing properties and physiological properties of the subject strain mainly
conform to
Shining, E.B. and D. Gottlieb: Methods for characterization of Streptoniyces
species. Int. J.
Syst. Bacteriol. 16, 313-340, 1966, and Waksman, S.A.: The Actinomycetes Vol.
2:
Classification, identification and description of genera and species: The
Williams and Wilkins
Co., Baltimore, 1961. Observation was made after culturing the strain at a
culture
temperature of 30 C and for a time period for culture of 14 days.
[0028]
The observation of morphology was carried out by culturing the strain in a
yeast
extract-starch agar medium and then observing the strain under an optical
microscope and a
scanning electron microscope. The yeast extract-starch agar was prepared by
preparing a
solution containing 2.0 g of powdered yeast extract S (manufactured by Wako
Pure Chemical
Industries, Ltd.), 10 g of soluble starch, and 16 g of agar in 1 L of tap
water, adjusting to pH =
7.2 with a 1 M aqueous solution of NaOH, and then sterilizing the solution in
an autoclave.
The growth temperature was determined with yeast extract-starch agar. The
utility of the
carbon source was determined in Pridoham and Gottlieb's medium (Pridoham, T.G.
and D.
Gottlieb: The utilization of carbon compounds by some Actinomycetales as an
acid for
species determination: J. Bacteriol. 56:107-114, 1948).
[0029]
The color names were taken from "Methuen Handbook of Colour" (Kornerup, A. and
J.H. Wanscher: Methuen Handbook of Colour, Methuen, London, 1978).
[0030]
The analysis of amino acids in the cell wall conformed to the method by Becker
et al.
(Becker, B., M.P. Lechevalier, R.E. Gordon and H.A. Lechevalier: Rapid
differentiation
between Nocardia and Streptomyces by paper chromatography of whole-cell
hydrolysates:
Appl. Microbiol. 12, 421-423, 1964).
[0031]
The base sequence of 16S rDNA was determined according to the method by
Nakagawa et al. (Nakagawa Yasuyoshi, and Kawasaki Hiroko, Classification and
Identification of Actinomycetes, pp. 83-117, 2001, edited by the Society for
Actinomycetes
Japan: Tokyo, Business Center for Academic Societies Japan).
[0032]
The homology search was carried out by using the FASTA search in the website
of
the National Institute of Genetics:
8
CA 02721051 2010-10-08
(a) http://www.ddbj.nig.ac.jp;
(b) D.J. Lipman, W.R. Pearson: Rapid and sensitive protein similarity
searches,
Science, 227, 1435-1441 (1985); and
(c) W.R. Pearson, D.J. Lipman: Improved tools for biological sequence
comparison,
Proc. Natl. Acad. Sci. USA, 85, 2444-2448 (1988).
The base sequence of 16S rDNA of a standard strain was obtained from the
database
of the National Institute of Genetics (http://www.ddbj.nig.ac.jp).
[0033]
The phylogenic tree was produced by a neighbor-binding method using Clustal W
package (Clustal W Thompson, J.D., Higgins, D.G. and Gibson, T.J.: CLUSTAL W:
improving the sensitivity of progressive multiple sequence alignment through
sequence
weighting, position-specific gap penalties and weight matrix choice. Nucleic
Acids Res. 22,
4673-4680, 1994).
[0034]
The DNA homology of Streptomyces sp. strain 6982 and its closely related
strains can
be confirmed by the method by Ezaki et al. shown in the following documents.
(a) Ezaki, T., Hashimoto, Y., Takeuchi, T., Yamamoto, H., Liu, S.-L., Matsui,
K &
Yabuuchi, E., J. Clin. Microbiol., 26, (1988) 1708-1713; and
(b) Ezaki, T., Hashimoto, Y. & Yabuuchi, E., Int. J. Syst. Bacteriol., 39,
(1989) 224-
229.
[0035]
In the present specification, the "closely related strain" means a strain
having at least
97% homology of the base sequence of 16S rDNA with Streptomyces sp. strain
6982. It is
known that if the homology of the base sequence of 16S rDNA is less than 97%,
those strains
are determined as different species.
Stackebrandt, E. & Goebel, B.M., Int. J Syst Bacteriol., 44, (1994) 846-849.
[0036]
(1) Morphological features
The substrate mycelium was developed well and branched irregularly. The aerial
mycelium exhibited an imperfect helical form, and was formed into 10 or more
fragmented
spore chains. The spores had smooth surfaces, an elliptical shape and a size
of 1.2 x 1.0 m.
Sclerotic granules, sporangia, fragmentation of substrate mycelium and motile
spores were
not observed.
9
CA 02721051 2010-10-08
[0037]
(2) Cultural properties
The aerial mycelium exhibited good epiphytism on yeast extract-starch agar,
yeast
extract-malt extract agar, oatmeal agar, inorganic salt-starch agar, and
glycerin-asparagine
agar, and weak epiphytism was recognized on tyrosine agar. Aerial mycelium
epiphytism
was not recognized on peptone-yeast extract-iron agar. The color of the aerial
mycelium was
grayish brown or brownish gray. The color of the reverse side of growth was
yellowish
brown, brownish beige, grayish yellow, pale yellow, brownish orange, and pale
orange.
Production of melanoid pigments was not recognized on tryptone-yeast extract
medium and
peptone-yeast extract-iron agar. Production of soluble pigments was not
recognized. The
somatic pigments did not change with the pH.
[0038]
The growth states on these various media are shown in Table 1. The
abbreviations
have the following meanings. G: growth, A: aerial mycelium, R: color of
reverse side of
growth, S: soluble pigment
CA 02721051 2010-10-08
[0039]
[Table 1]
Medium Growth state
Yeast extract-malt extract G Good
agar (ISP-2) A Rich, filamentous, grayish brown (7E3)
R Yellowish brown (5D6)
S None
Oatmeal agar (ISP-3) G Good
A Rich, filamentous, brownish gray (6E2)
R Brownish beige (6E3)
S None
Inorganic salt-starch agar G Good
(ISP-4) A Rich, brownish gray (6E2)
R Grayish yellow (4B5)
S None
Glycerin-asparagine agar G Good
(ISP-5) A Rich, filamentous, brownish gray (7E2)
R Pale yellow (4A3)
S None
Peptone-yeast extract-iron G Medium degree
agar (ISP-6) A None
R Brownish orange (5C6)
S None
Tyrosine agar (ISP-7) G Good
A Pale white
R Pale orange (5A3)
S None
[0040]
(3) Cell wall type
The whole-cell degradation product was analyzed, and as a result, the presence
of LL-
diaminopimelic acid as an amino acid was confirmed.
[0041]
(4) Physiological properties
The utility of D-glucose, sucrose, D-xylose, D-fructose, L-rhamnose,
raffinose, L-
arabinose, inositol and D-mannitol was positive. Table 2 shows the
physiological
characteristics of Streptomyces sp. strain 6982.
11
CA 02721051 2010-10-08
[0042]
[Table 2]
Condition Characteristics
Growth temperature ( C) 12-45
Optimal growth temperature ( C) 28-43
Production of melanoid pigment -
Production of soluble pigment -
Utility of carbon source
D-Glucose ++
Sucrose +
D-Xylose ++
D-Fructose +
L-Rhamnose +
Raffinose ++
L-Arabinose ++
Inositol +
D-Mannitol +
[0043]
(5) Analysis based on 16S rDNA base sequence
The 16S rDNA partial base sequence of Streptomyces sp. strain 6982 is shown in
the
attached Sequence Listing. As a result of the homology search, Streptomyces
glaucescens
strain DSM40716 (Accession No: X79322) having 99.2% homology was the most
closely
related strain. The homology with Streptomyces albus strain NBRC 13014
(Accession No:
AB 184257), which is a standard strain of the standard species of the genus
Streptomyces, was
96.2%. Furthermore, in the phylogenic tree produced based on the 16S rDNA
partial base
sequence, the strain formed identical clusters with the various species of
Streptomyces.
[0044]
(6) Identification
From the results of the morphological observation, chemical analysis and
analysis
based on the 16S rDNA base sequence with reference to the following documents
(a) to (d), it
has been concluded that the subject strain belongs to the genus Streptomyces.
(a) Euzeby, J.P.: List of bacterial names with standing in nomenclature: a
folder
available on the internet. Int. J. Syst. Bacteriol., 1997, 47, pp. 590-592.
(b) Waksman, S.A., et al.: The nomenclature and classification of the
actinomycetes.
Journal of Bacteriology, 1943, 46, pp. 337-341.
(c) Williams, S.T.: Bergey's Manual of Systematic Bacteriology, Vol. 4. 1989.
12
CA 02721051 2010-10-08
(d) Zhang, Z. et al.: A proposal to revive the genus Kitastospora, Int. J.
Syst.
Bacteriol., 1997, 47, pp. 1048-1054.
[0045]
Thus, the subject strain was designated as Streptomyces sp. strain 6982. The
subject
strain was deposited internationally at the International Patent Organism
Depositary (IPOD)
National Institute of Advanced Industrial Science and Technology, under the
Accession
Number FERM BP-10802 (Date of deposit: March 22, 2007).
Since microorganisms undergo artificial or natural mutations, Streptomyces sp.
strain
6982 of the invention includes, in addition to the microorganism isolated from
nature, the
strains obtained by artificially mutating the naturally isolated strain with
ultraviolet radiation,
X-rays, or chemicals, and natural mutants thereof.
[0046]
The aminosugar derivative of the invention can be obtained by inoculating a
microorganism which belongs to the genus Streptomyces and is capable of
producing a
compound having an a-amylase activity, preferably a microorganism capable of
producing
the relevant aminosugar derivative, and more preferably Streptomyces sp.
strain 6982, into a
medium containing nutrient sources, and aerobically growing the microorganism.
[0047]
The medium used in the culture may be any medium in which the microorganism
used can grow, and a synthetic medium, a semi-synthetic medium or a natural
medium can be
used.
[0048]
As the nutrients, it is desirable to use the nutrient sources that can be
utilized by the
strain of the invention. Examples of the nutrient sources include, as nitrogen
sources,
inorganic or organic nitrogen sources such as soybean flour, defatted soybean
flour, peptone,
meat extract, corn steep liquor, cotton seed flour, peanut flour, soy flour,
yeast extract, dry
yeast, NZ-amine, hydrolytic product of casein, fish powder, sodium nitrate,
and ammonium
nitrate. Examples of carbon sources include carbohydrates such as starches
such as potato
starch and corn starch, molasses, dextrin, sucrose, glucose, maltose,
trehalose, fructose,
xylose, rhamnose, mannitol and glycerin, or fats. Preferable examples include
starches and
soybean flour.
[0049]
Furthermore, sulfates, chlorates, nitrates, phosphates,. carbonates and the
like of Na,
K, Mg, Ca, Zn and Fe and the like are added as metal salts if necessary, and
preferable
13
CA 02721051 2010-10-08
examples include calcium carbonate and/or sodium chloride. Moreover, if
necessary,
conventionally known amino acids, growth promoting compounds such as methyl
oleate, lard
oil, silicone oil and surfactants, or defoamants are appropriately used. In
addition to these,
any substances that can be used by the producing bacteria and are helpful to
the production of
the compound of the invention, can be used as desired.
[0050]
Culture may be carried out in the same manner as in the culture for the
production of
general antibiotic substances, and the culturing method may be either solid
culture or liquid
culture. In the case of liquid culture, any of standing culture, shaking
culture and stirring
culture may be carried out, and for example, aeration-agitation culture may be
carried out.
In regard to the culturing conditions, the culturing temperature that can be
appropriately
applied may be a temperature at which the producing strain can grow and
produce the
compound of the invention, that is, in the range of 15 to 42 C, and a
temperature of about 20
to 30 C is preferable, and a temperature of 23 to 27 C is more preferable. A
pH that can be
appropriately applied is in the range of 4 to 9, and pH 6 to 8 is preferable.
The culturing
time may vary with various conditions, and usually a time period in the range
of 1 to 30 days
can be appropriately applied, and a time period of 4 to 10 days is preferable.
[0051]
In order to isolate the desired compound from the culture, conventional means
for
extraction, separation and purification that are used upon the isolation of
metabolic products
of microorganisms can be appropriately used. The substance in the culture is
obtained by
filtering the culture liquid directly, or filtering after centrifuging the
culture liquid or adding a
filtration aid to the culture, and thus a filtrate is obtained. At this time,
an organic solvent
such as acetone, MeOH, EtOH, or MeCN may be added to the culture liquid, or
hydrochloric
acid or the like may be added for pH adjustment, if desired. Furthermore, the
substance can
be separated by bringing the filtrate into contact with an appropriate carrier
to adsorb the
produced substance in the filtrate, and then eluting the substance with an
appropriate solvent.
For example, the filtrate is brought into contact with a porous adsorption
resin such as
AMBERLITE (registered trademark) XAD2, DIAION (registered trademark) HP20,
DIAION
CHP20P, or DIAION SP850, and thereby the substance is adsorbed. Subsequently,
a liquid
mixture of water and an organic solvent such as acetone, MeOH, EtOH or MeCN is
used to
elute the substance. Hydrochloric acid or the like may also be added for pH
adjustment, if
desired. In this case, a fraction containing the substance may be obtained
efficiently by
14
CA 02721051 2010-10-08
gradually or continuously increasing the mixing ratio of the organic solvent
from low
concentration to high concentration.
[0052]
The compound of the invention was purified by adding a base, in order to
eliminate
any compound that is unstable and is difficult to isolate as a single product,
such as a reducing
sugar compound. Furthermore, the compound was repeatedly purified so as to
secure the
purity for a medicine.
[0053]
The compound of formula (I) is isolated and purified as a free compound, a
salt
thereof, a hydrate, a solvate or a crystal polymorphic substance. A salt of
the compound of
formula (I) can be produced by subjecting the compound to a salt-producing
reaction of a
conventional method. Isolation and purification are carried out by applying
conventional
chemical operations such as extraction, fractionated crystallization, and
various fractionated
chromatography techniques.
[0054]
According to the present specification, the term "recovery" means an operation
carried out to obtain the compound (I) of the invention as a simple substance
or as a
composition, and includes "purification" or "isolation".
[0055]
According to the present specification, the "purification" includes operations
carried
out for the purpose of "isolating" the compound of the invention, and the
compound of the
invention may be "isolated" by "purification".
[0056]
Various isomers can be produced by selecting appropriate starting compounds,
or can
be separated by using the differences in the physicochemical properties
between isomers.
For example, an optical isomer may be obtained by a general optical resolution
method for
racemic bodies (for example, fractional crystallization induced by a
diastereomer salt with an
optically active base or acid, chromatography using a chiral column or the
like).
[0057]
According to the present specification, the term "chromatography" means the
chromatography technique generally used in analytical chemistry, and examples
include, but
not limited to, gas chromatography (GC), liquid chromatography (LC), and
supercritical fluid
chromatography (SFC).
CA 02721051 2010-10-08
[0058]
According to the present specification, the "liquid chromatography (LC)" means
the
generic name for chromatographic techniques using liquid in the mobile phase,
and examples
include, but not limited to, medium performance liquid chromatography and high
performance liquid chromatography (HPLC).
[0059]
A composition containing the compound of formula (I) or a salt thereof means a
composition obtainable in the stage of purifying or isolating the compound of
formula (I), and
means a composition that can be used as a production source for a medicine. An
example of
the composition is, but not limited to, a mixture of one kind or two or more
kinds of the
compound of formula (I) or a salt thereof with an active ingredient such as
acarviostatin IV03,
or with other components. The subject composition contains the compound of
formula (I) or
a salt thereof at a proportion of, but not limited to, about 80% or more,
preferably 85% or
more, more preferably 90% or more, even more preferably 95% or more, and still
more
preferably 98% or more, in terms of area percentage as obtained by an analysis
by
chromatography.
[0060]
A pharmaceutical composition containing one kind or two or more kinds of the
compound of formula (I) or a salt thereof as active ingredients, can be
prepared according to a
conventionally used method, using the excipients that are conventionally used
in this area that
is, excipients for medicaments, carriers for medicaments or the like.
Administration may be carried out either by oral administration by means of
tablets,
pills, capsules, granules, powders or liquids, or by parenteral administration
by means of
intraarticular, intravenous or intramuscular injections, suppositories, eye
drops, eye ointments,
transdermal liquids, ointments, transdermal patches, transmucosal liquids,
transmucosal
patches, inhalants or the like.
[00611
As solid compositions for oral administration, tablets, powders, granules and
the like
are used. In these solid composition, one kind or two or more kinds of active
ingredients are
mixed with at least one inert excipient, for example, lactose, mannitol,
glucose,
hydroxypropyl cellulose, microcrystalline cellulose, starch,
polyvinylpyrrolidone, and/or
magnesium metasilicate aluminate. The composition may contain inert additives,
for
example, a lubricating agent such as magnesium stearate, a disintegrant such
as
carboxymethylstarch sodium, a stabilizer, and a dissolution aid, according to
a conventional
16
CA 02721051 2010-10-08
method. The tablets or pills may be coated with a sugar coating or a film of a
gastric or
enteric substance, if necessary.
[0062]
Examples of the liquid composition for oral administration include
pharmaceutically
acceptable emulsions, solutions, suspensions, syrups elixirs, and the like,
and the liquid
composition contains a generally used inert diluent, for example, purified
water or EtOH.
The liquid composition may also contain, in addition to the inert diluent,
auxiliary agents such
as a solubilizer, a wetting agent and a suspending agent, as well as a
sweetening agent, a
flavoring agent, a fragrance and a preservative.
[0063]
The injection for parenteral administration contains a sterile aqueous or non-
aqueous
solution, suspension or emulsion. Examples of an aqueous solvent include
distilled water
for injection, and physiological saline. Examples of a non-aqueous solvent
include
propylene glycol, polyethylene glycol, plant oils such as olive oil, alcohols
such as EtOH,
Polysorbate 80 (name according to the Japanese Pharmacopoeia), and the like.
Such a
composition may further contain an isotonic agent, a preservative, a wetting
agent, an
emulsifier, a dispersant, a stabilizer or a dissolution aid. These
compositions are sterilized
by, for example, filtration through a bacteria-retaining filter, incorporation
of a bactericide, or
irradiation. Furthermore, these compositions may be used by preparing a
sterile solid
composition, and dissolving or suspending the solid composition in sterilized
water or a
sterilized solvent for injection prior to use.
[0064]
Agents for external use include an ointment, a plaster, a cream, a jelly, a
PAP, a spray,
a lotion, an eye drop, an eye ointment, and the like. These agents contain
generally used
ointment bases, lotion bases, aqueous or non-aqueous liquids, suspensions
emulsions and the
like. Examples of the ointment or lotion bases include polyethylene glycol,
propylene
glycol, white petrolatum, bleached beeswax, polyoxyethylene hydrogenated
castor oil,
glycerin monostearate, stearyl alcohol, cetyl alcohol, lauromacrogol, sorbitan
sesquioleate and
the like.
[0065]
For the transmucosal preparations such as an inhalant and an intranasal agent,
solid,
liquid or semisolid preparations are used, and the preparations can be
produced according to
conventionally known methods. For example, the preparation may appropriately
contain
known excipients, a pH adjusting agent, a preservative, a surfactant, a
lubricating agent, a
17
CA 02721051 2010-10-08
stabilizer, a thickening agent and the like. The preparations can be
administered by using an
appropriate device for inhalation or in sufflation. For example, the compound
can be
administered alone, or as a powder of a prescribed mixture, or as a solution
or suspension in
combination with a pharmaceutically acceptable carrier, by using a known
device such as a
metered dose inhalation device, or a sprayer. A dry powder inhaler or the like
may be a
device for single administration or multiple administrations, and a dry powder
or powder-
containing capsules can be used. Alternatively, the preparation may be in the
form of an
appropriate ejection preparation, for example, a pressurized aerosol spray
using a suitable gas
such as chlorofluoroalkane, hydrofluoroalkane or carbon dioxide.
[0066]
Typically, in the case of oral administration, the daily dose is suitably
about 0.01 to
100 mg/kg, and preferably 0.1 to 10 mg/kg, per body weight, and this dose is
administered
once or in 2 to 4 divided portions. Furthermore, in the case of a transmucosal
preparation, a
dose of about 0.001 to 100 mg/kg per body weight is administered once or in
several divided
portions a day. The dose is appropriately determined in accordance with the
individual
cases, in consideration of symptoms, age, gender and the like.
[0067]
The compound of formula (I) can be used together with various therapeutic
agents or
prophylactic agents for diseases against which the compound of formula (I) is
believed to
exhibit effectiveness. The combined preparation may be administered
simultaneously, or
separately but continually, or with a desired time interval. A preparation for
simultaneous
administration may be a mixed preparation or may be in separate preparations.
EXAMPLES
[0068]
Hereinafter, the process for producing the compound of formula (I) will be
described
in more detail based on Examples. The invention is not intended to be limited
to the
compounds described in the following Examples. Furthermore, the process for
production
of the compound of formula (I) is not intended to be limited to the specific
production
processes of the Examples shown below, and the compound of formula (I) can
also be
produced according to a combination of these production processes, or
according to a method
obvious to those ordinarily skilled in the art.
[0069]
The following abbreviations may be used in the present specification.
18
CA 02721051 2010-10-08
EtOH: ethanol
MeCN: acetonitrile
MeOH: methanol
NaCl: sodium chloride
NaOH: sodium hydroxide
TFA: trifluoroacetic acid
[0070]
Hereinafter, the invention will be described in more detail based on Examples,
but the
invention is not at all intended to be limited to these Examples.
[0071]
Example 1
(Culture)
A seed medium was prepared by dispensing 30 mL each of a medium (pH = 7.0)
containing 20 g of a soluble starch, 10 g of Pinedex #3 (manufactured by
Matsutani Chemical
Industry Co., Ltd.), 20 g of a soybean flour and 1 L of distilled water, into
erlenmeyer flasks
each having a capacity of 100 mL, and sterilizing the medium in an autoclave
at 121 C for 30
minutes.
One platinum loop of a slant culture product of Streptomyces sp. strain 6982
was
inoculated into this seed medium, and the inoculated seed medium was subjected
to shaking
culture for 3 days at 30 C.
A production medium was prepared by dispensing 30 mL each of a medium (pH =
7.0) containing 100 g of a soluble starch, 60 g of a soybean flour, 2.5 g of
NaCl, 2 g of CaCO3
and 1 L of distilled water, into erlenmeyer flasks each having a capacity of
100 mL, and
sterilizing the medium in an autoclave at 121 C for 30 minutes.
The seed culture medium obtained as described above was inoculated into each
flask
of this production medium, in an amount of 2 mL each, and the resultant
mixtures were
subjected to shaking culture for 7 days at 25 C.
[0072]
Crude purification from culture medium
22 L of the culture liquid obtained by the culturing method described above
was
adjusted to pH = 3 with a 6 M aqueous HCl solution, and then the adjusted
culture medium
was suction filtered. The filtrate was adjusted to pH = 7 with a 6 M aqueous
NaOH solution,
and then the adjusted filtrate was applied to DIAION HP20 (resin amount 1.2
L). The
19
CA 02721051 2010-10-08
column was washed with a 10% aqueous McOH solution and then eluted with a 25%
aqueous
MeOH solution.
[0073]
This active fraction was applied to DOWEX 50W X1 (manufactured by the Dow
Chemical Company) cation exchange resin (resin amount 550 mL). The column was
washed with distilled water, a 0.5 M aqueous NaCl solution and a 1 M aqueous
NaCl solution,
and then eluted with a 3 M aqueous NaCl solution.
Subsequently, the active fraction was applied to DAISOGEL SP-120-15/30-ODS-B
(resin amount 1L, manufactured by Daiso Co., Ltd.). The column was eluted with
a 10%
aqueous MeOH solution and a 15% aqueous MeOH solution to obtain compounds A
and B,
respectively, and the column was eluted with a 20% aqueous MeOH solution and a
25%
aqueous MeOH solution to obtain compound C.
[0074]
(1) Purification and isolation of compound A
The active fraction containing compound A, which was obtained by purifying by
ODS column chromatography, was applied to SP-120-15/30-ODS-B (resin amount 337
mL).
The column was eluted with a 2% aqueous McOH solution and a 3% aqueous McOH
solution
(each containing 0.05% TFA).
This active fraction was adjusted to pH = 13 with a 6 M aqueous NaOH solution,
and
was applied to DIAION HP20SS (resin amount 500 mL)). The column was eluted
with a
12.5% aqueous MeOH solution and a 15% aqueous MeOH solution (each containing
0.05 M
NaOH).
The active fraction was adjusted to pH = 7 with a 6 M aqueous HCI solution,
and was
applied to DIAION HP20 (resin amount 200 mL) and the column was eluted with a
50%
aqueous MeOH solution. The eluate was concentrated under reduced pressure, and
then was
freeze-dried to obtain 1.14 g of a powder.
200 mg of the powder was dissolved in water, and the solution was applied to
DAISOPAK SP-120-5-ODS-BP (20 x 250 mm, manufactured by DAISO Co., Ltd.). The
column was eluted with a 2% aqueous MeCN solution (containing 0.05% TFA).
This active fraction was adjusted to pH = 7 with a 6 M aqueous NaOH solution,
and
was applied to DIAION HP20 (resin amount 50 mL). The column was eluted with a
50%
aqueous MeOH solution. The eluate was concentrated under reduced pressure, and
was
freeze-dried to obtain 136 mg of a powder.
CA 02721051 2010-10-08
The powder was dissolved in water, and the solution was applied to DAISOPAK SP-
120-5-ODS-BP (20 x 250 mm). The column was eluted with a 2% aqueous MeCN
solution
(containing 0.05% TFA).
This active fraction was adjusted to pH = 7 with a 6 M aqueous NaOH solution,
and
was applied to DIAION HP20 (resin amount 30 mL). The column was eluted with a
50%
aqueous MeOH solution.
The obtained active fraction was concentrated under reduced pressure, and was
freeze-dried to obtain compound A (65 mg).
[0075]
(2) Purification and isolation of compound B
The fraction obtained by crude purification by ODS column chromatography was
applied to SP-120-15/30-ODS-B (resin amount 337 mL). The column was eluted
with a
series of 3% to 7% aqueous MeOH solutions (each containing 0.05% TFA).
This active fraction was adjusted to pH = 13 with a 6 M aqueous NaOH solution,
and
was applied to DIAION HP20SS (resin amount 250 mL). The column was eluted with
15%,
17.5% and 20% aqueous MeOH solutions (each containing 0.05 M NaOH).
This active fraction was adjusted to pH = 7 with a 6 M aqueous HCl solution,
and
was applied to DIAION HP20 (resin amount 150 mL). The column was eluted with a
50%
aqueous MeOH solution. The eluate was concentrated under reduced pressure, and
then was
freeze-dried to obtain 970 mg of a powder.
450 mg of the powder was dissolved in water, and the solution was applied to
DAISOPAK SP-120-5-ODS-BP (20 x 250 mm). The column was eluted with a 2.2%
aqueous MeCN solution (containing 0.05% TFA).
This active fraction was adjusted to pH = 7 with a 6 M aqueous NaOH solution,
and
was applied to DIAION HP20 (resin amount 115 mL). The column was eluted with a
50%
aqueous McOH solution. The eluate was concentrated under reduced pressure, and
was
freeze-dried to obtain 190 mg of a powder.
The powder was dissolved in water, and the solution was applied to DAISOPAK SP-
120-5-ODS-BP (20 x 250 mm). The column was eluted with a 2.2% aqueous MeCN
solution (containing 0.05% TFA)
This active fraction was adjusted to pH = 7 with a 6 M aqueous NaOH solution,
and
was applied to DIAION HP20 (resin amount 30 mL). The column was eluted with a
50%
aqueous MeOH solution.
21
CA 02721051 2010-10-08
The obtained active fraction was concentrated under reduced pressure, and was
freeze-dried to obtain compound B (129 mg).
[0076]
(3) Purification and isolation of compound C
The fraction obtained by crude purification by ODS column chromatography was
applied to SP-120-15/30-ODS-B (resin amount 80 mL). The column was eluted with
a 2%
aqueous MeOH solution (each containing 0.05% TFA).
This active fraction was adjusted to pH = 13 with a 6 M aqueous NaOH solution,
and
was applied to DIAION HP20SS (resin amount 200 mL). The column was eluted with
15%,
17.5% and 20% aqueous MeOH solutions (each containing 0.05 M NaOH).
This active fraction was adjusted to pH = 7 with a 6 M aqueous HCl solution,
and
was applied to DIAION HP20 (resin amount 150 mL). The column was eluted with a
50%
aqueous MeOH solution. The eluate was concentrated under reduced pressure, and
then was
freeze-dried to obtain 1 g of a powder.
The powder was dissolved in water, and the solution was applied to DAISOPAK SP-
120-5-ODS-BP (20 x 250 mm). The column was eluted with a series of 2.2% to
3.2%
aqueous MeCN solutions (each containing 0.05% TFA).
This active fraction was adjusted to pH = 7 with a 6 M aqueous NaOH solution,
and
was applied to DIAION HP20 (resin amount 30 mL). The column was eluted with a
50%
aqueous MeOH solution. The eluate was concentrated under reduced pressure, and
was
freeze-dried to obtain 236 mg of a powder.
184 mg of the powder was dissolved in water, and the solution was applied to
DAISOPAK SP-120-5-ODS-BP (20 x 250 mm). The column was eluted with a 2.2%
aqueous MeCN solution (containing 0.05% TFA).
This active fraction was adjusted to pH = 7 with a 6 M aqueous NaOH solution,
and
was applied to DIAION HP20 (resin amount 30 mL). The column was eluted with a
50%
aqueous MeOH solution.
The obtained active fraction was concentrated under reduced pressure, and was
freeze-dried to obtain compound C (91 mg).
[0077]
Physicochemical properties of compounds A, B and C
The compounds A, B and C obtained by extraction, separation and purification
respectively had the following physicochemical properties.
(1) Compound A
22
CA 02721051 2010-10-08
1) Color and shape: white powder
2) Classification by acidity, neutrality and basicity: basic
3) Specific rotation: [a]23D +157 (c = 0.5, H2O)
4) Molecular formula: C94H156N4O64
5) High resolution TOF-mass spectrum:
Found value [M+2H]2+ 1183.4624
Theoretical value [M+2H]2+ 1183.4616
6) Elemental analysis: as C94H156N4O64 14H20
Calculated value: C 43.12, H 7.08, N 2.14,
Found value: C 43.27, H 7.08, N 2.05
7) Solubility: highly soluble in water, DMF and DMSO, but slightly soluble in
acetone, MeOH, EtOH and MeCN.
8) Ultraviolet absorption spectrum (solvent: water): shows end absorption
9) Infrared absorption spectrum (v,,,ax (KBr) cm-'): 3330, 2925, 1655, 1385,
1150,
1040, 93 5
10) 1H-NMR spectrum (500 MHz, D20): shown in FIG 1
11) 13C-NMR spectrum (125 MHz, D20): shown in FIG 2
[0078]
(2) Compound B
1) Color and shape: white powder
2) Classification by acidity, neutrality and basicity: basic
3) Specific rotation: [a]23D +153 (c = 0.5, H2O)
4) Molecular formula: C113H187N5O76
5) High resolution TOF-mass spectrum:
Found value [M+2H]2+ 1416.0548
Theoretical value [M+2H]2+ 1416.0539
6) Elemental analysis: as C113H187N5O76 16H20
Calculated value: C 43.50, H 7.08, N 2.24,
Found value: C 43.53, H 7.09, N 2.15
7) Solubility: highly soluble in water, DMF and DMSO, but slightly soluble in
acetone, MeOH, EtOH and MeCN.
8) Ultraviolet absorption spectrum (solvent: water): shows end absorption
9) Infrared absorption spectrum (vm,, (KBr) cm-'): 3365, 2930, 1640, 1385,
1150,
1045, 935
23
CA 02721051 2010-10-08
10) 1H-NMR spectrum (500 MHz, D20): shown in FIG 3
11) 13C-NMR spectrum (125 MHz, D20): shown in FIG. 4
[0079]
(3) Compound C
1) Color and shape: white powder
2) Classification by acidity, neutrality and basicity: basic
3) Specific rotation: [a]23D +172 (c = 0.5, H2O)
4) Molecular formula: C132H218N6088
5) High resolution TOF-mass spectrum:
Found value [M+2H]2+ 1648.6467
Theoretical value [M+2H]2+ 1648.6462
6) Elemental analysis: as C132H218N6088 16H20
Calculated value: C 44.22, H 7.03, N 2.34,
Found value: C 44.23, H 7.09, N 2.35
7) Solubility: highly soluble in water, DMF and DMSO, but slightly soluble in
acetone, MeOH, EtOH and MeCN.
8) Ultraviolet absorption spectrum (solvent: water): shows end absorption
9) Infrared absorption spectrum (v,,,ax (KBr) cm-'): 3365, 2925, 1635, 1340,
1150,
1040, 935
10) 1H-NMR spectrum (500 MHz, D20): shown in FIG 5
11) 13C-NMR spectrum (125 MHz, D20): shown in FIG 6
The chemical structures of the compounds A, B and C were determined as shown
below, from the physicochemical properties described above.
[Chem. 7]
CH OH CH3 CH2OH CH2OH CH2OH OH
2
O O O 0 2OH
OH OH OH OH OH ro H
0 H 0 0 OH 0 OH 0OH
H OH OH OH n
wherein compound A: n = 4; compound B: n = 5; and compound C: n = 6.
24
CA 02721051 2010-10-08
[0080]
When the compounds A, B and C produced by the method described above were
analyzed by a high performance liquid chromatography (HPLC) method under the
conditions
shown below, the area percentages (%) of the compounds A, B and C were 99.0%,
98.2% and
98.3%, respectively. The area percentage (%) was determined by designating the
sum of the
peak areas of the respective compounds obtained from a chromatogram for the
retention time
in the range of 6 minutes to 22 minutes, as 100, and calculating the ratios of
peak areas of the
respective components with respect to the sum of peak areas. The HPLC
chromatograms of
the compound A to the compound C are shown in FIG. 9 to FIG 11.
1) Column: Unison US-C18 250-4.6 mm (manufactured by Imtakt Corp.)
2) Mobile phase: 1-7% aqueous MeCN solution (containing 0.05% TFA) (0 to 20
minutes)
3) Flow rate: 1.0 ml/min
4) Detection: UV, 210 rim.
5) Column temperature: 50 C
6) Retention time: compound A 16.3 minutes, compound B 17.9 minutes, compound
C 19.2 minutes
(Reference Document: Chemistry Handbook: Applied Chemistry, 6th Edition
(Maruzen Corp.), Chapter 8 Analysis, Measurement, Management, p. 342-346)
[0081]
Example 2
The a-amylase inhibitory activity of the compound of the invention was
verified by
the following method.
(1) Experiment method
The solutions of pancreatic a-amylases of mouse, rat, dog and monkey were
prepared
from the pancreases of an ICR mouse (male, 8 weeks old, purchased from SLC
Japan, Inc.),
an SD rat (male, 8 weeks old, purchased from Charles River Laboratories Japan,
Inc.), a
beagle dog (male, 35 months old, purchased from Narc Corp.), and a cynomolgus
monkey
(male, 10 years old, purchased from CLEA Japan, Inc.). The solutions of a-
amylases from
human saliva and pancreas were prepared from the enzymes purchased from Sigma-
Aldrich
Co. These a-amylase solutions were all diluted to 800 U/mL using an assay
buffer (48 mM
NaCl, 5.4 mM KCI, 28 mM Na2HPO4, 43 mM NaH2PO4, 35 mM mannitol, pH = 7.0). The
various a-amylase solutions (20 U, 25 L) and the compounds dissolved in the
assay buffer
(25 L) were added to a 96-well microplate, and the microplate was incubated
at 37 C for 10
CA 02721051 2010-10-08
minutes. Subsequently, a starch solution (5 mg/mL, 50 L) was added thereto,
and the
microplate was incubated at 37 C for 10 minutes. A O.33 M perchloric acid
solution (50 L)
was added to the microplate to terminate the enzymatic reaction, and then a
0.01 M iodine
solution (50 L) was added thereto to color the solutions. The absorbance (660
nm) of each
of the solutions was measured. The concentration of the compound inhibiting
50% of the a-
amylase activity was calculated as the IC50 value.
(2) Results
The compounds of the invention have an inhibitory activity against all kinds
of the a-
amylases examined. The inhibitory activity (IC50 value) of the compounds A, B
and C
against the mouse pancreatic a-amylase were 1.90 nM, 2.06 nM and 1.73 nM,
respectively;
the inhibitory activity (IC50 value) against the rat pancreatic a-amylase were
2.01 nM, 2.12
nM and 1.95 nM, respectively; the inhibitory activity (IC50 value) against the
dog pancreatic
a-amylase were 2.06 nM, 2.38 nM and 2.07 nM, respectively; the inhibitory
activity (IC50
value) against the monkey pancreatic a-amylase were 2.14 nM, 1.90 nM and 2.02
nM,
respectively; the inhibitory activity (IC50 value) against the human saliva a-
amylase were
2.20 nM, 1.87 nM and 1.99 nM, respectively; and the inhibitory activity (IC50
value) against
the human pancreatic a-amylase were 2.02 nM, 2.11 nM and 2.21 nM,
respectively.
[0082]
Example 3
The oral activity of the compounds of the invention was verified by the
following
method.
(1) Experiment method
Male ICR (normal) mice (6 weeks old, purchased from SLC Japan, Inc.) were used
for the animal. The compound was prepared into a solution using a 0.5%
methylcellulose
solution. Blood was collected from a mouse which had been fasted overnight,
for the
measurement of the blood glucose level and the blood plasma insulin level, and
the mouse
was orally administered with a solvent or the compound A (0. 3, 1, 3, 10
mg/kg), immediately
followed by oral administration of a carbohydrate solution (75 mg/mL starch,
25 mg/mL
sucrose, 20 mL/kg). Subsequently, blood was collected 0.25, 0.5 and 1 hour
after the oral
administration, for the measurement of the blood plasma insulin level, and
blood was
collected 0.5, 1 and 2 hours after the oral administration, for the
measurement of the blood
glucose level.
The blood glucose level was measured by using Glucose CII-test Wako reagent
(Wako Pure Chemical Industry, Ltd.), and the blood plasma insulin
concentration was
26
CA 02721051 2010-10-08
measured by using a Mouse Insulin ELISA Kit (Shibayagi Co., Ltd.). The test
results are
indicated in the average standard error.
The area-under-curve (AUC) of the blood glucose level-time curve was
calculated
from the blood glucose level for the time period up to 2 hours from the
administration of the
compound, and the AUC of the plasma insulin level-time curve was calculated
from the blood
plasma insulin level for the time period up to 1 hour from the administration
of the
compound. A statistical analysis was performed between the solvent-
administered group
and the compound A-administered group by using Dunnett's multiple range test,
and a critical
rate of less than 5% was defined as significant.
(2) Results
A dose-dependent blood glucose elevation suppressive action was recognized by
the
oral administration of the compound A (0.3 to 10 mg/kg), and the action was
significant for a
dose of 1 mg/kg or greater (FIG 7). This time, a dose-dependent, significant
plasma insulin
level lowering action was also recognized (FIG 8).
[0083]
Example 4
The disaccharide hydrolase inhibitory activity of the compounds of the
invention was
verified by the following method.
(1) Experiment method
The brush border cell samples produced from the small intestines of an ICR
mouse,
an SD rat, a beagle dog and a cynomolgus monkey, and a human small intestinal
microsome
sample (BD Biosciences; Lot 36869) were used as various disaccharide hydrolase
solutions.
These disaccharide hydrolase solutions and the compounds were all prepared
using a
phosphate buffer (NaCl 48 mM, KC15.4 mM, Na2HPO4 28 mM, NaH2PO4 43 mM, and
mannitol 35 mM, pH = 6.0).
Evaluation on mouse, rat, dog and monkey disaccharide hydrolase inhibitory
activity:
The disaccharide hydrolase solutions (10 mg/mL, 40 L) and compound solutions
(20 L)
were added to a 96-well microplate, and the microplate was incubated for 10
minutes at 37 C.
Subsequently, substrates for the disaccharide hydrolases (sucrase: 100 mM
sucrose, maltase:
100 mM maltose, isomaltase: 100 mM isomaltose, lactase: 100 mM lactose,
trehalase: 100
mM trehalose, 40 L) were added to the microplate, and the microplate was
incubated for 30
minutes at 37 C. A O.04 M perchloric acid solution (100 L) was added to the
microplate to
terminate the reaction, and then the solutions were centrifuged (2,000 rpm, 15
minutes). The
glucose concentrations in the supernatants were measured using Glucose CII-
test Wako
27
CA 02721051 2010-10-08
reagent (Wako Pure Chemical Industry, Ltd.). The disaccharide hydrolase
inhibitory activity
was calculated relative to non-enzyme-added samples (0%) and non-compound-
added
samples (100%).
Evaluation on human disaccharide hydrolase inhibitory activity: The
disaccharide
hydrolase solutions (0.1 mg/mL, 20 L) and compound solutions (10 L) were
added to a 96-
well microplate, and the microplate was incubated for 10 minutes at 37 C.
Subsequently,
substrates for the disaccharide hydrolases (sucrase: 100 mM sucrose, maltase:
100 mM
maltose, isomaltase: 100 mM isomaltose, lactase: 100 mM lactose, trehalase:
100 mM
trehalose, 20 L) were added to the microplate, and the microplate was
incubated for 30
minutes at 37 C. A O.04 M perchloric acid solution (100 L) was added to the
microplate to
terminate the reaction, and then the solutions were centrifuged (2,000 rpm, 15
minutes). The
glucose concentrations in the supernatants were measured using Glucose CII-
test Wako
reagent (Wako Pure Chemical Industry, Ltd.). The disaccharide hydrolase
inhibitory activity
was calculated relative to non-enzyme-added samples (0%) and non-compound-
added
samples (100%).
(2) Results
The compounds of the invention did not exhibit an inhibitory activity against
any of
the disaccharide hydrolases (sucrase, maltase, isomaltase, lactase and
trehalase) brought under
test (IC50 > 10 M).
[0084]
As a result of the tests described above, it was confirmed that the compound
of
formula (I) has an a-amylase inhibitory action, and a blood glucose level and
blood plasma
insulin level lowering action, and it was confirmed that the compound can be
used for the
treatment of diabetes and the like.
Industrial Applicability
[0085]
The compound of formula (I) or a salt thereof has an a-amylase inhibitory
action and
can be used as a prophylactic or therapeutic agent for diabetes, obesity, NASH
(non-alcoholic
steatohepatitis) and the like. The compound or a salt thereof is also expected
to be able to
inhibit the absorption of glucose without causing symptoms in the digestive
system such as
diarrhea, unlike the glucosidase inhibitors.
28
CA 02721051 2010-10-08
Sequence Listing Free Text
[0086]
The 16S rDNA partial base sequence of Streptomyces sp. strain 6982 is shown in
the
Sequence Listing.
29
